Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.
The Ash meeting starts on December 1. Here are some haematological cancer presentations that investors will be focusing on, as biotech risks ending 2018 in poor shape.
Once hotly tipped approaches from Aduro, Tesaro and Merck & Co might yet hold promise, but disappointing early data cuts have burst the bubble of investor…
The next generation of CAR-T therapies is already emerging.